Q-omics provides the consensus-scored PDE8A profile across patient tissues and cancer cell-line models. PDE8A expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, PDE8A is differentially expressed in 13, with the highest sampling consensus in HNSC. Additionally, PDE8A RNA expression shows 20,923 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight ACC, HNSC, and UVM as cancer lineages where PDE8A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PDE8A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PDE8A survival associations across molecular data types. PDE8A RNA expression shows survival associations in the most cancer types (23), followed by mutation status (8) and mass-spec protein abundance (9). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PDE8A RNA expression–survival associations across cancer types. High PDE8A expression shows unfavorable associations in ACC, CESC, STAD and LGG, but favorable associations in KIRC and COAD. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for PDE8A RNA expression.
This table summarizes PDE8A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 8. The strongest signals are observed in HNSC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for PDE8A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PDE8A shows lower tumor expression in COAD, THCA, KICH and BRCA and higher tumor expression in HNSC and KIRC. The HNSC box plot shows higher PDE8A RNA expression in tumor versus normal tissue (log2 FC = +0.704, t-test p < 0.001).
This table shows molecular features associated with PDE8A in patient tissues and cancer cell lines. In patient samples, PDE8A shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, PDE8A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and BLOOD_Leukemia.
